Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and gastroenterology. The company's current commercial offerings include Gvoke, a pre-mixed liquid glucagon formulated for managing severe hypoglycemia. It also provides Keveyis, a specific therapy for various forms of primary periodic paralysis, including hyperkalemic and hypokalemic types.